Alignment Healthcare, Inc. $ALHC Shares Bought by Royce & Associates LP

Royce & Associates LP boosted its stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 23.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 514,060 shares of the company’s stock after acquiring an additional 97,000 shares during the period. Royce & Associates LP owned 0.26% of Alignment Healthcare worth $8,970,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Royal Bank of Canada lifted its position in shares of Alignment Healthcare by 92.6% during the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after purchasing an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock worth $1,109,000 after buying an additional 2,594 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Alignment Healthcare by 79.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock worth $18,112,000 after acquiring an additional 429,703 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Alignment Healthcare in the 1st quarter worth approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Alignment Healthcare by 16.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after acquiring an additional 44,452 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Insider Transactions at Alignment Healthcare

In other news, CEO John E. Kao sold 605,648 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $11,349,843.52. Following the transaction, the chief executive officer directly owned 2,234,294 shares of the company’s stock, valued at approximately $41,870,669.56. This trade represents a 21.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert L. Scavo sold 69,541 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $1,303,198.34. Following the completion of the sale, the insider directly owned 503,014 shares of the company’s stock, valued at $9,426,482.36. The trade was a 12.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 2,125,938 shares of company stock valued at $41,799,570. 6.60% of the stock is currently owned by corporate insiders.

Alignment Healthcare Price Performance

NASDAQ ALHC opened at $18.45 on Wednesday. The company has a 50-day moving average price of $20.96 and a two-hundred day moving average price of $18.63. Alignment Healthcare, Inc. has a 52 week low of $11.63 and a 52 week high of $23.87. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -1,843.16, a price-to-earnings-growth ratio of 3.12 and a beta of 1.18. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.99.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.53% and a negative net margin of 0.02%.The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm posted ($0.16) earnings per share. The business’s revenue was up 44.4% on a year-over-year basis. Analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ALHC shares. KeyCorp restated an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lifted their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen upgraded shares of Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. UBS Group raised their target price on shares of Alignment Healthcare from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, January 14th. Finally, TD Cowen upped their target price on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a report on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $24.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.